YTHDC2 Promotes Malignant Phenotypes of Breast Cancer Cells

Table 1

Association between YTHDC2 expression and clinicopathological parameters.

Variable		YTHDC2 expression				value
		0	1+	2+	3+
All cases	99	28	36	15	20
Age (years)
≤60	43	14	14	9	6	0.413^†
>60	56	14	22	6	14
Stage
I	49	17	18	9	5	0.032^‡
IIA	30	7	11	3	9
IIB	6	3	1	0	2
IIIA	1	0	1	0	0
IIIB	6	1	3	1	1
IIIC	3	0	1	2	0
IV	4	0	1	0	3
Subtype
Luminal A	31	11	8	6	6	0.882^†
Luminal B	46	10	20	8	8
HER2 enriched	9	2	4	0	3
Triple negative	13	5	4	1	3
ER
Negative	22	7	8	1	6	0.878^†
Positive	77	21	28	14	14
PgR
Negative	38	12	16	3	7	0.295^†
Positive	61	16	20	12	13
HER2
Negative	85	23	30	15	17	0.402^†
Positive	14	5	6	0	3

^†Determined using the Kruskal–Wallis test; ^‡determined using the Spearman rank correlation coefficient.